PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:

C12N 15/12, A61K 48/00

(11) International Publication Number:

WO 98/58956

A3

(43) International Publication Date:

30 December 1998 (30.12.98)

(21) International Application Number:

PCT/US98/12894

(22) International Filing Date:

19 June 1998 (19.06.98)

(81) Designated States: AU, CA, CN, JP, KR, NZ, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT,

LU, MC, NL, PT, SE).

(30) Priority Data:

08/880,979

23 June 1997 (23.06.97)

US

Published

With international search report.

LUDWIG INSTITUTE FOR CANCER RE-SEARCH [CH/US]; 605 Third Avenue, New York, NY

10158 (US).

(72) Inventors: WARNIER, Guy; Institute Ludwig pour la Recherche sur le Cancer, Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). UYTTENHOVE, Catherine; Institute Ludwig pour la Recherche sur le Cancer, Avenue Hippocrate 74, UCL 7459, B-1200 Brussels (BE). BOON-FALLEUR, Thierry; Institute Ludwig pour la

7459, B-1200 Brussels (BE).

(74) Agent: VAN AMSTERDAM, John, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).


Recherche sur le Cancer, Avenue Hippocrate 74, UCL

(88) Date of publication of the international search report:

18 March 1999 (18.03.99)

(54) Title: METHODS FOR INDUCING AN IMMUNE RESPONSE INVOLVING PRIME-BOOST PROTOCOLS

Adeno.P1A: priming i.d. ears Peptide: boost. Two injections s.c. in the two footpads.



(57) Abstract

This invention relates to improved methods for modulating an immune response against an antigen using adenoviruses which express the antigen for priming immunization and antigen peptides for booster immunizations. Preferably the peptides are combined with QS21/MPL adjuvant. In particular, immunization methods for tumor antigens are provided. Kits for immunization are also provided.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	$\mathbf{U}\mathbf{Z}$	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

PC., JS 98/12894

A. CLASSIFICATION OF SUBJECT MATTER I PC 6 C12N15/12 A61K48/00							
According to International Patent Classification (IPC) or to both national classification and IPC							
B. FIELDS	SEARCHED						
Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61K							
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched							
Electronic d	ata base consulted during the international search (name of data ba	se and, where practical, search terms used)					
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT						
Category °	Citation of document, with indication, where appropriate, of the rel	evant passages	Relevant to claim No.				
X	WARNIER G ET AL: "Induction of cytolytic T-cell response in micrecombinant adenovirus coding fo antigen P815A." INTERNATIONAL JOURNAL OF CANCER, 17) 67 (2) 303-10. JOURNAL CODE: ISSN: 0020-7136., UNITED STATES, XP002079472 see the whole document and note especially comments on in paragraphs 3 and 6	e with a r tumor (1996 JUL GQU.	1-14, 25-32				
X Further documents are listed in the continuation of box C. Patent family members are listed in annex.							
"A" docume conside "E" earlier of filing de "L" docume which i citation "O" docume other n "P" docume later th	nt which may throw doubts on priority claim(s) or s cited to establish the publication date of another or other special reason (as specified) ont referring to an oral disclosure, use, exhibition or	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family Date of mailing of the international search report					
	nailing address of the ISA	Authorized officer					
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		SITCH, D					

1

INTERNATIONAL SEARCH REPORT

Interpotional Application No
PC., US 98/12894

		<u></u>
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ZHAI Y ET AL: "Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100." JOURNAL OF IMMUNOTHERAPY, (1997 JAN) 20 (1) 15-25. JOURNAL CODE: CUQ., UNITED STATES, XP002036182 see page 15 see abstract	1-14, 25-32
A	FRANCHINI ET AL: "Highly Attenuated HIV Type 2 Recombinant Poxviruses, but Not HIV-2 Recombinant Salmonella Vaccines, Induce Long-Lasting Protection in Rhesus Macaques" AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 11, 1995, pages 909-920, XP002079473 see page 909 see abstract	1-14, 25-32
4	PIALOUX ET AL: "A Prime-Boost Approach to HIV Preventive Vaccine Using a Recombinant Canarypox Virus Expressing Glycoprotein 160 (MN) followed by a Recombinant Glycoprotein 160 (MN/LAI)" AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 11, 1995, pages 373-381, XP002079474 see page 373 see abstract	1-14, 25-32

1

INTERNATIONAL SEARCH REPORT

Ir national application No.

PCT/US 98/12894

Box i	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)			
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claims 1-14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.			
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:			
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).			
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)			
This Inte	mational Searching Authority found multiple inventions in this international application, as follows:			
see	FURTHER INFORMATION sheet			
	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.			
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.			
	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:			
(No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1,2,5-14,25-30 (all partially) 3,4,31,32 (all completely)			
Remark o	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.			

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1, 2, 5-14, 25-30 (all partially), 3, 4, 31, 32 (all completely)

A method for inducing an immune response in a mammal against an antigen comprising administering a virus containing a nucleic acid encoding the antigen or its precursor, and administering at least one booster dose comprising at least one peptide in an adjuvant, wherein the at least one peptide includes the antigen, and wherein the antigen is a tumour antigen; a kit for use in such a method.

2. Claims: 1, 2, 5-14, 25-30 (all partially)

A method for inducing an immune response in a mammal against an antigen comprising administering a virus containing a nucleic acid encoding the antigen or its precursor, and administering at least one booster dose comprising at least one peptide in an adjuvant, wherein the at least one peptide includes the antigen, and wherein the antigen is an antigen characteristic of a pathogen; a kit for use in such a method.

3. Claims: 15-24 (all completely)

A method for reducing an immune response in a mammal against an antigen comprising administering a virus containing a nucleic acid encoding the antigen or its precursor, and administering at least one booster dose comprising at least one peptide in a non-adjuvant carrier, wherein the at least one peptide includes the antigen.